Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2022 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, Aug 6, 2021
Slide 1: Investor Presentation Q1FY22
Investor Presentation Q1FY22 August 6, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q1FY22
Key Highlights of Q1FY22 Good start to the financial year with strong growth in the India Business • Revenue from Operations grew by 37.1% YoY during the quarter, with EBITDA margin of 21.7% and Net Profit growth of 10.9% YoY • India Business: Company’s secondary sales registered growth of 61.1% YoY
Slide 4: Key Financial Highlights – Q1FY22 (Consolidated)
Key Financial Highlights – Q1FY22 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 19,097 27,314 11,550 19,920 Q1FY21 Q1FY22 International sales 7,853 7,903 Q1FY21 Q1FY22 Q1FY21 Q1FY22
Slide 5: Key Financial Highlights – Q1FY22 (Consolidated)
Key Financial Highlights – Q1FY22 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,366 5,929 12,581 5,217 63.2% 59.9% 26.2% 21.7% Q1FY21 Q1FY22 Q1FY21 Q1FY22 PBT (before Minority Interest) PAT (after Minority Interest) 4,681 5,561 4,220 4,928 Q1FY21 Q1FY22
Slide 6: India Business
India Business India Business: Q1FY22 Sales of ₹ 19,097 million (65.3% YoY growth) • India sales contributed 70.7% to total sales in Q1FY22 • In Q1FY22, the Company’s secondary sales grew by 61.1% YoY compared to IPM growth of 39.2% YoY (Source: IQVIA data) • Growth was mainly led by acute therapies
Slide 7: Secondary Sales Performance
Secondary Sales Performance Robust growth across all the major therapeutic segments in Q1FY22 -1 +2 Market rank 1 3 4 2 Acute Therapies 88.5% 93.6% 86.6% 43.7% 46.8% 32.8% 33.2% 36.3% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth YoY1,2 Indian p
Slide 8: US Business
US Business US Business: Q1FY22 Sales of ₹ 6,043 million (YoY decline of 9.3%) • US sales contributed 22.4% to total sales in Q1FY22 • During the quarter, the US business registered sequential growth of 11.2% over Q4FY21 • In Q1FY22, the Company filed 2 ANDAs with the US FDA and received 5 final app
Slide 9: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 2 observations. Already sent a detail response to the St. Louis (US) Formulations June 2021 US FDA on the corrective and preventive actions being taken Baddi (India) Formulations Februar
Slide 10: Other International Business
Other International Business Other International Business: Q1FY22 Sales of ₹ 1,860 million (56.4% YoY growth) • Other International Market sales contributed 6.9% to total sales in Q1FY22 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets lik
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on June 30, 2021 Non-Institution, 22.17% Promoter & Promoter Group, 58.84% Institution, 18.99% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodie
Slide 12: Thank You
Thank You For further information or queries, please contact Gagan Borana Investor Relations Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com